Arcturus CMO Steve Hughes steps down; Kelly Lindert named Chief Development Officer, Vaccines

Arcturus Therapeutics Holdings Inc.

Dr. Steve Hughes resigns as CMO effective Feb 14, 2022, to become Strategic Clinical Advisor.
Dr. Kelly Lindert, formerly SVP and Head of Vaccines, appointed Chief Development Officer, Vaccines.
Hughes will continue supporting Arcturus programs in an advisory capacity.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Steve Hughes

Chief Medical Officer

ARCT · Arcturus Therapeutics Holdings Inc.

Effective: 2022-02-14
Filed: February 11, 2022, 6:59 PM ET

Effective February 14, 2022, Dr. Steve Hughes will step down from his position as Chief Medical Officer of Arcturus Therapeutics Holdings Inc.

Appointed

Kelly Lindert

Chief Development Officer, Vaccines

ARCT · Arcturus Therapeutics Holdings Inc.

Effective: 2022-02-14
Filed: February 11, 2022, 6:59 PM ET

Dr. Kelly Lindert, the Company’s Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Hughes departed as Chief Medical Officer at Arcturus Therapeutics Holdings Inc..

Action: stepped down
Role: Chief Medical Officer

Exact text from the filing

Effective February 14, 2022, Dr. Steve Hughes will step down from his position as Chief Medical Officer of Arcturus Therapeutics Holdings Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kelly Lindert was appointed as Chief Development Officer, Vaccines at Arcturus Therapeutics Holdings Inc..

Action: appointed
Role: Chief Development Officer, Vaccines

Exact text from the filing

Dr. Kelly Lindert, the Company’s Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the Company.

View on SEC.gov

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-22-000265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.